België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

synthon b.v. - tamsulosinehydrochloride 0,4 mg - capsule met gereguleerde afgifte, hard - 0,4 mg - tamsulosinehydrochloride 0.4 mg - tamsulosin

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

chemo iberica s.a. - hydrochloorthiazide 12,5 mg; telmisartan 40 mg - tablet - 40 mg - 12,5 mg - telmisartan 40 mg; hydrochloorthiazide 12.5 mg - telmisartan and diuretics

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

chemo iberica s.a. - telmisartan 80 mg; hydrochloorthiazide 12,5 mg - tablet - 80 mg - 12,5 mg - telmisartan 80 mg; hydrochloorthiazide 12.5 mg - telmisartan and diuretics

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

chemo iberica s.a. - hydrochloorthiazide 25 mg; telmisartan 80 mg - tablet - 80 mg - 25 mg - telmisartan 80 mg; hydrochloorthiazide 25 mg - telmisartan and diuretics

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - telmisartan 40 mg; hydrochloorthiazide 12,5 mg - tablet - 40 mg - 12,5 mg - telmisartan 40 mg; hydrochloorthiazide 12.5 mg - telmisartan and diuretics

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - hydrochloorthiazide 12,5 mg; telmisartan 80 mg - tablet - 80 mg - 12;5 mg - telmisartan 80 mg; hydrochloorthiazide 12.5 mg - telmisartan and diuretics

België - Nederlands - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

laboratorios liconsa s.a. - telmisartan 80 mg; hydrochloorthiazide 25 mg - tablet - 80 mg - 25 mg - telmisartan 80 mg; hydrochloorthiazide 25 mg - telmisartan and diuretics

Europese Unie - Nederlands - EMA (European Medicines Agency)

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. , drievoudige combinatietherapie) als aanvulling op dieet en lichaamsbeweging bij patiënten die onvoldoende gecontroleerd op hun maximale getolereerde dosis van metformine en een enz.). sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Europese Unie - Nederlands - EMA (European Medicines Agency)

accord healthcare s.l.u. - metformin hydrochloride, vildagliptin - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - vildagliptin/metformin hydrochloride accord is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:- in patients who are inadequately controlled with metformin hydrochloride alone. - in patients who are already being treated with the combination of vildagliptin and metformin hydrochloride, as separate tablets. - in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 en 5. 1 voor de beschikbare gegevens over verschillende combinaties).

Europese Unie - Nederlands - EMA (European Medicines Agency)

sun pharmaceutical industries europe b.v. - sitagliptin fumarate, metformin hydrochloride - diabetes mellitus, type 2 - geneesmiddelen die worden gebruikt bij diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride sun is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride sun is indicated in combination with a sulphonylurea (i. , drievoudige combinatietherapie) als aanvulling op dieet en lichaamsbeweging bij patiënten die onvoldoende gecontroleerd op hun maximale getolereerde dosis van metformine en een enz.). sitagliptin/metformin hydrochloride sun is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. sitagliptin/metformin hydrochloride sun is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.